Pharma Industry News

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Clinical benefit correlated with increase in target biomarker SIGMAR1

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]